Teva Pharmaceutical Industries Ltd (TEVA) 56.77 $TEVA
Mylan Sees A Sentiment Shift From A Top 3 Institutional Holder
Dallas Salazar - at Seeking Alpha - Fri Feb 13, 10:52AM CST
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Teva Is The Drug Industry's Comeback Story
Saibus Research - at Seeking Alpha - Fri Feb 13, 2:09AM CST
TEVA: 56.77 (-0.58)
Teva Pharmaceutical - I Don't Think This Is The Time To Buy It
Khen Elazar - at Seeking Alpha - Thu Feb 12, 7:16PM CST
TEVA: 56.77 (-0.58)
Teva commences debt offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:37AM CST
TEVA: 56.77 (-0.58)
Teva Announces $1 Billion Debt Tender Offer
Business Wire - Thu Feb 12, 7:26AM CST
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has commenced tender offers (the "Offers"
to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $1 billion (the "Maximum Amount" of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
TEVA: 56.77 (-0.58)
The Top ADRs To Buy This Week
Todd Campbell - at Seeking Alpha - Thu Feb 12, 6:40AM CST
RUK: 71.70 (-1.02), BUD: 121.72 (-0.80), ANW: 14.92 (+0.25), DEG: 21.85 (-0.05), ENL: 50.46 (-0.66), FBR: 13.05 (-0.23), SNE: 27.30 (+0.19), TM: 132.49 (+0.67), RDY: 54.15 (-0.01), LUX: 58.79 (-1.11), OMAB: 38.76 (-0.66), TTM: 48.34 (+0.42), SNN: 35.82 (-0.28), RYAAY: 61.46 (-2.33), EDAP: 3.55 (+0.13), AZN: 69.96 (+0.20), TRIB: 17.30 (-0.12), EFA: 63.82 (+0.42), WX: 41.53 (+0.45), TEVA: 56.77 (-0.58)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Synthetic Biologics: A Speculative Small Cap Packed With Power
Jerad W. Starr - Seeking Alpha - Tue Feb 10, 8:19AM CST
I reserve a portion of my portfolio for small biotechnology companies. Those who invest in this sector know that these stocks are very volatile and can rise or fall 50% on major news or trial results. With that in mind, I believe one can typically...
SYN: 2.13 (+0.18), TEVA: 56.77 (-0.58)
Teva Files 2014 Annual Report on Form 20-F
Business Wire - Tue Feb 10, 1:51AM CST
In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) ("Teva" announced today that it has filed its 2014 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Teva Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by phone at (215) 591-8912.
TEVA: 56.77 (-0.58)
Teva Pharmaceutical Industries Falls 2.15% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 4:08PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $56.26 to a high of $57.79. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $56.27 on volume of 5.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 56.77 (-0.58)
Research and Markets: Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
Business Wire - Mon Feb 09, 1:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/l6vx9x/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering.
ABT: 46.09 (+0.87), TEVA: 56.77 (-0.58)
Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
M2 - Mon Feb 09, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgfvvc/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering. The API market in the US to grow at a CAGR of 7% over the period 2014-2019 Active pharmaceutical ingredients (API) are active substances that are used in the manufacture of drugs and that have pharmacological effects. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. API may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology and for treatment of conditions such as respiratory disorders and rheumatoid arthritis. One major trend upcoming in the market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy. According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents. Further, the report states that stringent regulationse one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors. Key Vendors - Abbott Laboratories - Aurobindo Pharma - Mylan - Teva Pharmaceutical Industries Other Prominent Vendors - Albemarle - Aptuit - BASF - Biocon - Boehringer Ingelheim - Cambrex - Cipla - Dr. Reddy's Laboratories - Hospira - Lonza Group - Novartis - Pfizer - Sigma-Aldrich - Sun Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - API Market in the US - Market Segmentation by Type of Production Process - Market Segmentation by Type of Product - Market Segmentation by Type of Players - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/jgfvvc/active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
5 Key Findings After 1 Full Year of Obamacare
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 8:51AM CST
Source: The White House via Flickr. The Affordable Care Act enrolled millions of Americans in health insurance plans during its first open enrollment period, which began in October of 2013 and ended in March 2014, and the first real-time results of...
CI: 114.47 (-0.51), ANTM: 141.05 (-0.95), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58)
Antares Pharma: Preparing For An Inflection Point
Mark Chapman - at Seeking Alpha - Sat Feb 07, 8:32AM CST
TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
Mylan Sees A Sentiment Shift From A Top 3 Institutional Holder
Dallas Salazar - at Seeking Alpha - Fri Feb 13, 10:52AM CST
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Teva Is The Drug Industry's Comeback Story
Saibus Research - at Seeking Alpha - Fri Feb 13, 2:09AM CST
TEVA: 56.77 (-0.58)
Teva Pharmaceutical - I Don't Think This Is The Time To Buy It
Khen Elazar - at Seeking Alpha - Thu Feb 12, 7:16PM CST
TEVA: 56.77 (-0.58)
Teva commences debt offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:37AM CST
TEVA: 56.77 (-0.58)
Teva Announces $1 Billion Debt Tender Offer
Business Wire - Thu Feb 12, 7:26AM CST
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has commenced tender offers (the "Offers"
to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $1 billion (the "Maximum Amount" of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: TEVA: 56.77 (-0.58)
The Top ADRs To Buy This Week
Todd Campbell - at Seeking Alpha - Thu Feb 12, 6:40AM CST
RUK: 71.70 (-1.02), BUD: 121.72 (-0.80), ANW: 14.92 (+0.25), DEG: 21.85 (-0.05), ENL: 50.46 (-0.66), FBR: 13.05 (-0.23), SNE: 27.30 (+0.19), TM: 132.49 (+0.67), RDY: 54.15 (-0.01), LUX: 58.79 (-1.11), OMAB: 38.76 (-0.66), TTM: 48.34 (+0.42), SNN: 35.82 (-0.28), RYAAY: 61.46 (-2.33), EDAP: 3.55 (+0.13), AZN: 69.96 (+0.20), TRIB: 17.30 (-0.12), EFA: 63.82 (+0.42), WX: 41.53 (+0.45), TEVA: 56.77 (-0.58)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Synthetic Biologics: A Speculative Small Cap Packed With Power
Jerad W. Starr - Seeking Alpha - Tue Feb 10, 8:19AM CST
I reserve a portion of my portfolio for small biotechnology companies. Those who invest in this sector know that these stocks are very volatile and can rise or fall 50% on major news or trial results. With that in mind, I believe one can typically...
SYN: 2.13 (+0.18), TEVA: 56.77 (-0.58)
Teva Files 2014 Annual Report on Form 20-F
Business Wire - Tue Feb 10, 1:51AM CST
In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) ("Teva"
announced today that it has filed its 2014 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Teva Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by phone at (215) 591-8912. TEVA: 56.77 (-0.58)
Teva Pharmaceutical Industries Falls 2.15% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 4:08PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $56.26 to a high of $57.79. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $56.27 on volume of 5.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 56.77 (-0.58)
Research and Markets: Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
Business Wire - Mon Feb 09, 1:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/l6vx9x/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering.
ABT: 46.09 (+0.87), TEVA: 56.77 (-0.58)
Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
M2 - Mon Feb 09, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgfvvc/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering. The API market in the US to grow at a CAGR of 7% over the period 2014-2019 Active pharmaceutical ingredients (API) are active substances that are used in the manufacture of drugs and that have pharmacological effects. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. API may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology and for treatment of conditions such as respiratory disorders and rheumatoid arthritis. One major trend upcoming in the market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy. According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents. Further, the report states that stringent regulationse one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors. Key Vendors - Abbott Laboratories - Aurobindo Pharma - Mylan - Teva Pharmaceutical Industries Other Prominent Vendors - Albemarle - Aptuit - BASF - Biocon - Boehringer Ingelheim - Cambrex - Cipla - Dr. Reddy's Laboratories - Hospira - Lonza Group - Novartis - Pfizer - Sigma-Aldrich - Sun Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - API Market in the US - Market Segmentation by Type of Production Process - Market Segmentation by Type of Product - Market Segmentation by Type of Players - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/jgfvvc/active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
5 Key Findings After 1 Full Year of Obamacare
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 8:51AM CST
Source: The White House via Flickr. The Affordable Care Act enrolled millions of Americans in health insurance plans during its first open enrollment period, which began in October of 2013 and ended in March 2014, and the first real-time results of...
CI: 114.47 (-0.51), ANTM: 141.05 (-0.95), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58)
Antares Pharma: Preparing For An Inflection Point
Mark Chapman - at Seeking Alpha - Sat Feb 07, 8:32AM CST
TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
